SCHEMBL9900191

SCHEMBL9900191

COc1c[c]nc(OC2CCCNC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.39
CHRNA4 P43681 3/20 0.39
ROCK1 Q13464 7/20 0.39
ROCK2 O75116 2/20 0.36
KCNH2 Q12809 1/20 0.36
IKBKB O14920 2/20 0.36
CHUK O15111 2/20 0.36
PRKX P51817 1/20 0.34
PRKCE Q02156 1/20 0.34
PRKCD Q05655 1/20 0.34
PRKD1 Q15139 1/20 0.34
MKNK1 Q9BUB5 2/20 0.34
PIM1 P11309 2/20 0.33
PIM2 Q9P1W9 2/20 0.33
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
P2RX7 Q99572 1/20 0.33
CNR2 P34972 1/20 0.33
PRKCI P41743 1/20 0.33
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9901501 0.73 CDK7 (0.41)
SCHEMBL224915 0.71 LMNA (0.38)
SCHEMBL21604531 0.69 CHRNB2 (0.49) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL9900071 0.67 CHRNB2 (0.49) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL3153942 0.66 CHRNB2 (0.55) CHRNB2CHRNA4ROCK1ROCK2KCNH2
Hydrochloric Acid SCHEMBL4103704 0.66 CHRNB2 (0.55) CHRNB2CHRNA4ROCK1ROCK2KCNH2
Hydrochloric Acid SCHEMBL4105363 0.66 CHRNB2 (0.55) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL30775387 0.66 CHRNB2 (0.47) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL20281437 0.64 CHRNB2 (0.56) CHRNB2CHRNA4ROCK1ROCK2KCNH2
SCHEMBL20281436 0.64 CHRNB2 (0.56) CHRNB2CHRNA4ROCK1ROCK2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP claimed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US disclosed
EP-2796456-A1 Bicyclic compounds as Pim inhibitors Amgen Inc. (US) 2014-10-29 EP disclosed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US disclosed
EP-2649065-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS Amgen Inc. (US) 2013-10-16 EP disclosed
WO-2012078777-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 CHRNB2 4878/4885CHRNA4 4880/4885ROCK1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.